Cargando…
Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation
BACKGROUND: Valacyclovir has been used for prophylaxis against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT). We investigated the efficacy and safety of high-dose Valacyclovir as pre-emptive therapy in patients with CMV antigenemia after HSCT. METHODS: In a ret...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471913/ https://www.ncbi.nlm.nih.gov/pubmed/26090121 http://dx.doi.org/10.1186/s12878-015-0028-2 |
_version_ | 1782376982770614272 |
---|---|
author | Ong, Shin-Yeu Truong, Ha-Thi-Thu Diong, Colin Phipps Linn, Yeh-Ching Ho, Aloysius Yew-Leng Goh, Yeow-Tee Hwang, William Ying-Khee |
author_facet | Ong, Shin-Yeu Truong, Ha-Thi-Thu Diong, Colin Phipps Linn, Yeh-Ching Ho, Aloysius Yew-Leng Goh, Yeow-Tee Hwang, William Ying-Khee |
author_sort | Ong, Shin-Yeu |
collection | PubMed |
description | BACKGROUND: Valacyclovir has been used for prophylaxis against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT). We investigated the efficacy and safety of high-dose Valacyclovir as pre-emptive therapy in patients with CMV antigenemia after HSCT. METHODS: In a retrospective single center study of 61 patients, we compared the rates of viral clearance, recurrent antigenemia and adverse events in patients with pp65 CMV antigenemia who received high dose Valacyclovir (n = 15), Valganciclovir (n = 16), and Foscarnet (n = 30). RESULTS: Overall, 60/61 (98 %) of cases achieved CMV antigenemia clearance by day 28, and no patient developed CMV disease. After adjusting for age, sex, diagnosis, CMV serological status, donor type, CMV antigen level, graft-versus-host disease (GVHD) therapy, and conditioning regimen, there were no significant differences in the rates of viral clearance at day 14 in patients who received Valganciclovir (0.18, 95 % confidence interval (CI) 0.01 to 2.15, p = 0.17) and Foscarnet (OR 0.22, 95 % CI 0.03 to 2.40, p = 0.22), compared with Valacyclovir (assigned OR = 1.00). Recurrent antigenemia by day 180 after clearance of the initial CMV episode occurred in 34/61 (56 %) of patients. Using the multivariate model adjusting for the same covariates, there were also no significant differences in secondary episodes of CMV between treatment groups. With regards to adverse effect monitoring, Foscarnet led to significantly increased creatinine levels (P = 0.009), while Valganciclovir led to significant decrease in neutrophil counts (P = 0.012). CONCLUSION: High dose Valacyclovir is a potential alternative to Valganciclovir and Foscarnet in the stable post-HSCT patient who has cytopenia and is not keen for inpatient treatment of CMV antigenemia. |
format | Online Article Text |
id | pubmed-4471913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44719132015-06-19 Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation Ong, Shin-Yeu Truong, Ha-Thi-Thu Diong, Colin Phipps Linn, Yeh-Ching Ho, Aloysius Yew-Leng Goh, Yeow-Tee Hwang, William Ying-Khee BMC Hematol Research Article BACKGROUND: Valacyclovir has been used for prophylaxis against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT). We investigated the efficacy and safety of high-dose Valacyclovir as pre-emptive therapy in patients with CMV antigenemia after HSCT. METHODS: In a retrospective single center study of 61 patients, we compared the rates of viral clearance, recurrent antigenemia and adverse events in patients with pp65 CMV antigenemia who received high dose Valacyclovir (n = 15), Valganciclovir (n = 16), and Foscarnet (n = 30). RESULTS: Overall, 60/61 (98 %) of cases achieved CMV antigenemia clearance by day 28, and no patient developed CMV disease. After adjusting for age, sex, diagnosis, CMV serological status, donor type, CMV antigen level, graft-versus-host disease (GVHD) therapy, and conditioning regimen, there were no significant differences in the rates of viral clearance at day 14 in patients who received Valganciclovir (0.18, 95 % confidence interval (CI) 0.01 to 2.15, p = 0.17) and Foscarnet (OR 0.22, 95 % CI 0.03 to 2.40, p = 0.22), compared with Valacyclovir (assigned OR = 1.00). Recurrent antigenemia by day 180 after clearance of the initial CMV episode occurred in 34/61 (56 %) of patients. Using the multivariate model adjusting for the same covariates, there were also no significant differences in secondary episodes of CMV between treatment groups. With regards to adverse effect monitoring, Foscarnet led to significantly increased creatinine levels (P = 0.009), while Valganciclovir led to significant decrease in neutrophil counts (P = 0.012). CONCLUSION: High dose Valacyclovir is a potential alternative to Valganciclovir and Foscarnet in the stable post-HSCT patient who has cytopenia and is not keen for inpatient treatment of CMV antigenemia. BioMed Central 2015-06-19 /pmc/articles/PMC4471913/ /pubmed/26090121 http://dx.doi.org/10.1186/s12878-015-0028-2 Text en © Ong et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ong, Shin-Yeu Truong, Ha-Thi-Thu Diong, Colin Phipps Linn, Yeh-Ching Ho, Aloysius Yew-Leng Goh, Yeow-Tee Hwang, William Ying-Khee Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation |
title | Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation |
title_full | Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation |
title_fullStr | Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation |
title_full_unstemmed | Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation |
title_short | Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation |
title_sort | use of valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471913/ https://www.ncbi.nlm.nih.gov/pubmed/26090121 http://dx.doi.org/10.1186/s12878-015-0028-2 |
work_keys_str_mv | AT ongshinyeu useofvalacyclovirforthetreatmentofcytomegalovirusantigenemiaafterhematopoieticstemcelltransplantation AT truonghathithu useofvalacyclovirforthetreatmentofcytomegalovirusantigenemiaafterhematopoieticstemcelltransplantation AT diongcolinphipps useofvalacyclovirforthetreatmentofcytomegalovirusantigenemiaafterhematopoieticstemcelltransplantation AT linnyehching useofvalacyclovirforthetreatmentofcytomegalovirusantigenemiaafterhematopoieticstemcelltransplantation AT hoaloysiusyewleng useofvalacyclovirforthetreatmentofcytomegalovirusantigenemiaafterhematopoieticstemcelltransplantation AT gohyeowtee useofvalacyclovirforthetreatmentofcytomegalovirusantigenemiaafterhematopoieticstemcelltransplantation AT hwangwilliamyingkhee useofvalacyclovirforthetreatmentofcytomegalovirusantigenemiaafterhematopoieticstemcelltransplantation |